Novartis blockbuster drug hit by scandal in Japan

Researchers in Japan have retracted studies that promoted the benefits of one of Novartis' (NVS) biggest sellers in the country, the heart medicine Diovan.

The withdrawals came after university led investigations found data had been tampered with to create false results.

At least eight hospitals have said they'll stop prescribing the drug.

However, the impact in the U.S. is seen as limited, partly because Diovan is well established to the point that it's patent has expired. The drug's Japanese IP protection is due to end in later this year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs